Your trusted destination for CME, CPD & Medical Education across the Middle East.
Best of ASCO 2026 provides a focused review of the most important research and clinical advances presented at the ASCO Annual Meeting, covering major cancer types, emerging therapies, precision medicine, immunotherapy, supportive care, and survivorship. The programme helps oncology professionals interpret new evidence and apply relevant advances to clinical practice and patient care.
Best of ASCO 2026 is an oncology-focused educational conference organized by the Omani Society of Oncology, designed to provide a concise review of the most significant research and clinical developments presented at the ASCO Annual Meeting 2026. The programme brings together oncology professionals to examine practice-changing research, emerging treatment approaches, and new evidence across major cancer types. The conference focuses on translating the latest international oncology evidence into practical clinical knowledge, with discussions covering advances in cancer treatment, targeted and precision therapies, immunotherapy, and disease-specific management. The programme is intended to help healthcare professionals evaluate new findings and understand their potential implications for patient care and clinical practice. Major areas of oncology covered include breast, gastrointestinal, lung, genitourinary, gynecologic, and hematologic cancers, as well as melanoma and other malignancies. The programme also addresses emerging therapeutics, molecular precision medicine, immunotherapy, supportive care, symptom management, and survivorship. As an ASCO Best of ASCO® licensed programme, the conference provides a curated review of clinically important research selected from the ASCO Annual Meeting, allowing participants to focus on evidence that may influence cancer treatment and standards of care.
Review of the latest targeted treatments and their efficacy in advanced breast cancer.
Recent guidelines and outcomes in the surgical and radiotherapeutic management of breast cancer.
Evaluating the role and impact of immunotherapeutic agents in gastrointestinal oncology.
Evidence-based strategies for treating metastatic and advanced colorectal cancer.
Updates on biomarker-driven therapies for Non-Small Cell Lung Cancer.
Advances in the detection and multidisciplinary management of early-stage lung malignancies.
New therapeutic modalities and clinical trial results for prostate cancer.
Current standards of care and emerging treatments for renal cell carcinoma.
Secure your seat and earn full credit eligibility with encrypted checkout.
Secure payment processing & PCI-aligned flow
